NCT05095649View on ClinicalTrials.gov

Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

August 15, 2025

Study Completion Date

February 15, 2026

Conditions
Chronic Graft vs Host Disease
Interventions
BIOLOGICAL

Regulatory T-cell enriched infusion

Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.

Trial Locations (1)

41011

RECRUITING

José Antonio Pérez Simón, Seville

All Listed Sponsors
lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER